神经血管单元功能障碍在发育和向治疗的分子机制
Xiuxiu Liu1,2, Ying Zhang3,4, Yanming Zhao3,4
1Medical Basic Research Innovation Center for Cardiovascular and Cerebrovascular Diseases, Ministry of Education, Nanjing, 211166, China. xiuxiuliu@njmu.edu.cn.
Neuroscience bulletin
|April 2, 2024
概括
的发病因子涉及神经血管单元的变化. 了解这些机制可以揭示生物标志物和药物点,以便更好地治疗和诊断.
科学领域:
- 神经学 神经学
- 神经科学是一个神经科学.
- 病理学 病理学 病理学
背景情况:
- 是一种神经系统疾病,由反复发作来定义.
- 发育,发育的过程,涉及复杂的细胞和分子变化.
- 目前的治疗重点是抗发作药物,但破坏发育至关重要.
研究的目的:
- 探索神经血管单元中的变化和分子机制在发育过程中.
- 为了确定潜在的生物标志物用于早期诊断.
- 发现干预的新型治疗点.
主要方法:
- 本综述综合了目前关于发性的研究.
- 专注于神经血管单元的变化.
- 检查了驱动发作的分子机制.
主要成果:
- 生包括神经元,神经和神经血管单元内内皮质的显著变化.
- 这些变化导致结构和功能障碍.
- 这些变化背后的分子通路正在被阐明.
结论:
- 了解发生过程中神经血管单元的变化是开发新的治疗方法的关键.
- 识别生物标志物和药物标可以改善诊断和患者的治疗结果.
- 针对发症的早期干预策略对于减少疾病负担至关重要.
相关概念视频
Arteries of the Lower Limbs
188
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
188
Antiepileptic Drugs: Glutamate Antagonists
338
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
338
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
288
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
288
Antiepileptic Drugs: GABAergic Pathway Potentiators
389
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
389
Antiepileptic Drugs: Potassium Channel Activators
180
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
180
Antiepileptic Drugs: Sodium Channel Blockers
530
Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
530


